Aktie A2PWSL PROTALIX BIOTHERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Protalix BioTherapeutics, Inc. TEL AVIV STOCK EXCHANGE

Aktien

A2PWSL

US74365A3095

PLX

Verzögert TEL AVIV STOCK EXCHANGE
Andere Börsenplätze
 16:24:48 21.03.2023 		% 5 Tage % 1. Jan.
732.5 ILa -.--% Intraday Chart für Protalix BioTherapeutics, Inc. +3.29% +69.68%
26.06. Transcript : Protalix BioTherapeutics, Inc. - Analyst/Investor Day
10.05. Transcript : Protalix BioTherapeutics, Inc., Q1 2024 Earnings Call, May 10, 2024

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Protalix BioTherapeutics to Present at the 2024 BIO International Convention
Protalix BioTherapeutics : PLX Corporate Presentation (May 2024)
Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results
Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Earnings Flash (PLX) PROTALIX BIOTHERAPEUTICS Reports Q1 Revenue $3.7M, vs. Street Est of $9.2M
Protalix: Q1 Earnings Snapshot
Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024
Protalix BioTherapeutics to Participate in the 2024 BIO CEO and Investor Conference
Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Protalix: Q3 Earnings Snapshot
Earnings Flash (PBDA) PROTALIX BIOTHERAPEUTICS Reports Q3 Revenue $10.3M
Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023
Protalix BioTherapeutics : PLX Corporate Presentation (October 2023)
Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
Protalix Biotherapeutics Appoints Eliot Richard Forster to Succeed Zeev Bronfeld as Chairman, Effective as of September 14, 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PWSL Aktie
  4. A2PWSL Aktie
  5. Nachrichten Protalix BioTherapeutics, Inc.
  6. Andere Sprachen